FDA approves the Mounjaro KwikPen and the Zepbound KwikPen

The FDA approved multi-dose KwikPen versions of both tirzepatide products on the same day, January 20, 2026. Eli Lilly can now sell Mounjaro KwikPen and Zepbound KwikPen in six strengths each, with every pen holding four fixed once-weekly doses ^[1][2].

The approvals came through supplemental new drug applications that had been pending for more than two years. Lilly filed the Mounjaro KwikPen supplement (NDA 215866/S-009) on September 28, 2023, and the Zepbound KwikPen supplement (NDA 217806/S-002) on November 15, 2023 ^[1][2]. The FDA issued action letters on both on January 29, 2025, and Lilly submitted complete responses on December 2, 2025 ^[1][2]. Both approval letters were signed by Lisa B. Yanoff, MD, deputy director of the FDA's Office of Cardiology, Hematology, Endocrinology, and Nephrology, minutes apart on the evening of January 20 ^[1][2].

What is in each pen

The KwikPen strengths mirror the existing tirzepatide dose ladder, but each device holds four weeks of medicine. Per the labeling, the presentations are 10 mg/2.4 mL for four 2.5 mg doses, 20 mg/2.4 mL for four 5 mg doses, 30 mg/2.4 mL for four 7.5 mg doses, 40 mg/2.4 mL for four 10 mg doses, 50 mg/2.4 mL for four 12.5 mg doses, and 60 mg/2.4 mL for four 15 mg doses. Each individual dose is 0.6 mL ^[3][4].

That is a different injection volume from the familiar single-dose pens and single-dose vials, which deliver 0.5 mL ^[3][4]. The KwikPen shares its concentration range with the multi-dose vial presentations that were already on the label ^[3][4].

The Instructions for Use describe the Zepbound KwikPen as a disposable, multi-dose, single-patient-use prefilled pen that requires a separate KwikPen-compatible pen needle, which is not included ^[6]. Users prime the pen before each weekly injection by turning the dose knob until two clicks, then pushing the knob and counting to five to see a drop of medicine ^[6]. For the dose itself, the knob is turned all the way until it stops and an icon appears in the dose window; the instructions specifically say not to count clicks when selecting the dose ^[6]. After four doses the pen locks out a full dose and is meant to be thrown away, including leftover medicine, which should not be injected or transferred into a syringe ^[6]. The instructions also say people who are blind or have vision problems should not use the pen without help from someone trained on it ^[6].

A new sharing warning

Both labels added a new Warnings and Precautions subsection 5.10, dated 01/2026: never share a KwikPen between patients, even if the pen needle is changed ^[3][4]. The patient instructions explain the reason plainly — sharing may give another person a serious infection or expose the user to one ^[6]. That warning applies to the KwikPen specifically because one device carries a month of doses and could be picked up by more than one household member.

Why it matters for patients

Practically, this is a packaging and delivery change, not a new medicine or a new indication. Tirzepatide's approved uses are unchanged: Mounjaro for type 2 diabetes in adults and children 10 and older, and to reduce major cardiovascular events in adults with type 2 diabetes at high risk ^[4]; Zepbound for weight reduction and long-term maintenance in adults with obesity or overweight plus a weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity ^[3]. The boxed warning about thyroid C-cell tumors in rats and the existing warnings on pancreatitis, gallbladder disease, kidney injury, and gastrointestinal reactions still apply ^[3][4].

What changes is handling. One pen covers four weeks, so a mistake in priming, dialing, or storage affects more than a single dose. One pharmacist quoted by Healio noted that a multi-dose pen can appeal to people who see single-use devices as wasteful or who struggle with vials and syringes ^[5].

What happens next

On February 23, 2026, Lilly said the Zepbound KwikPen was available, with self-pay pricing starting at $299 per month for the 2.5 mg dose ^[5]. Pricing for higher KwikPen strengths, insurance coverage, and the launch timing for the Mounjaro KwikPen are not stated in these sources. Lilly was required to submit final printed carton and container labeling within 30 days of printing, including a change of "mg/dose" to "mg per dose" for clarity ^[1][2].